Education
About Us
Working with TipRanks
Follow Us
Genmab (Otc) (GMAB)
:GMAB
Total Valuation
Genmab has a market cap or net worth of $11.24B. The enterprise value is $13.14B.
Market Cap$11.24B
Enterprise Value$13.14B
Share Statistics
Genmab has 661.97M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding661.97M
Owened by Insiders
Owened by Instutions2.39%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 14.13%.
Return on Equity (ROE)21.38%
Return on Assets (ROA)17.12%
Return on Invested Capital (ROIC)14.13%
Return on Capital Employed (ROCE)16.55%
Revenue Per Employee$8,026,099.925
Profits Per Employee$2,924,683.072
Employee Count2,682
Asset Turnover0.47
Inventory Turnover15.89
Valuation Ratios
The current PE Ratio of Genmab is 12.39. Genmab’s PEG ratio is 0.15.
PE Ratio12.39
PS Ratio4.51
PB Ratio2.65
Price to Fair Value2.65
Price to FCF12.81
Price to Operating Cash Flow12.50
PEG Ratio0.15
Income Statement
In the last 12 months, Genmab had revenue of $21.53B and earned $7.84B in profits. Earnings per share was $121.44.
Revenue$21.53B
Gross Profit$20.54B
Operating Income$6.88B
Pretax Income$9.16B
Net Income$7.84B
EBITDA7.21B
Earnings Per Share (EPS)121.44
Cash Flow
In the last 12 months, operating cash flow was $7.77B and capital expenditures -$197.00M, giving a free cash flow of $7.57B billion.
Operating Cash Flow$7.77B
Free Cash Flow$7.57B
Free Cash Flow per Share$11.44
Dividends & Yields
Genmab pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield78.06%
Earnings Yield8.07%
Stock Price Statistics
Beta0.61
52-Week Price Change-38.45%
50-Day Moving Average20.50
200-Day Moving Average23.13
Relative Strength Index (RSI)35.10
Average Volume (3m)1.61M
Important Dates
Genmab upcoming earnings date is May 8, 2025, During Market Hours.
Last Earnings DateFeb 12, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Genmab as a current ratio of 5.25, with Debt / Equity ratio of 0.03
Current Ratio5.25
Quick Ratio5.24
Debt to Market Cap0.00
Net Debt to EBITDA-1.19
Interest Coverage Ratio55.86
Taxes
In the past 12 months, Genmab has paid $1.32B in taxes.
Income Tax$1.32B
Effective Tax Rate14.40%
Enterprise Valuation
Genmab EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.12.
EV to Sales0.04
EV to EBITDA0.12
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.11
Balance Sheet
Genmab has $21.10B in cash and marketable securities with $1.03B in debt, giving a net cash position of -$20.07B billion.
Cash & Marketable Securities$21.10B
Total Debt$1.03B
Net Cash-$20.07B
Net Cash Per Share-$30.32
Tangible Book Value Per Share$337.58
Margins
Gross margin is 95.42%, with operating margin of 31.14%, and net profit margin of 36.44%.
Gross Margin95.42%
Operating Margin31.14%
Pretax Margin42.57%
Net Profit Margin36.44%
EBITDA Margin34.33%
EBIT Margin32.89%
Analyst Forecast
The average price target for Genmab is $60.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$60.60
Price Target Upside236.48%
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast30.43%
EPS Growth Forecast82.29%